LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease
- LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSβ
- Unique mechanism of action with potential to slow or stop the progression of HD
Cambridge, UK, 6 January 2026 – LoQus23 Therapeutics Ltd (“LoQus23”), a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myotonic dystrophy type 1, and other triplet repeat expansion diseases, today announces that it has nominated, and is progressing, LQT-23, a drug candidate which has groundbreaking potential to slow or stop the progression of HD.
